28 December 2020 - Y-mAbs Therapeutics today announced that it has entered into a definitive agreement to sell its priority review voucher to United Therapeutics, based on an agreed valuation of $105 million.

The PRV was granted in conjunction with the approval by the U.S. FDA of Danyelza, for the treatment of refractory/relapsed high-risk neuroblastoma.

Read Y-mAbs press release